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boundaries. All of the cases analyzed have typical features of
HHD suggesting several possible causes of this discrepancy.
First, we cannot detect large deletions spanning the entire
coding region of ATP2C1 with our detection system. Second,
we cannot detect intronic mutations, mutations in the promoter
regions, or mutations in the 3¢-untranslated region. The fact
that Hu et al (2000) detected only 21 mutations out of a
possible 61 HHD cases using the same primer sets supports our
®ndings.
Among the ®ve families in which we could determine muta-
tions, those with missense mutations (cases 2 and 3) and the one
with a nonsense mutation in exon 25 (case 4) were predicted to
produce abnormal ATP2C1 protein. These three cases showed
early clinical symptoms (before the age of 40) compared with those
with nonsense mutations in the 5¢ proximal exons (cases 1 and 5).
In cases 1 and 5, severely reduced amounts of ATP2C1 protein are
expected to be found because of ``nonsense-mediated mRNA
decay'' (Frischmeyer and Dietz, 1999; Hentze and Kulozik, 1999).
mRNA that has a nonsense mutation at the 5¢ proximal region
would result in breakage because of the mechanism that is called
``nonsense-mediated mRNA decay'', and no abnormal truncated
protein would be translated. On the other hand, mRNA that has a
missense mutation or a nonsense mutation close to the end of the
gene could be translated, and abnormal protein could interfere
the action of normal ATP2C1 protein. Although HHD has
been considered to be the result of haploinsuf®ciency of the
ATP2C1 gene, the dominant negative effects of abnormal
ATP2C1 protein might also contribute to the disease phenotype.
Our data provide a signi®cant addition to the HHD mutation
database and will contribute further to the understanding of HHD
genotype/phenotype correlations and to the pathogenesis of this
disease.
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Unusual Pemphigus Phenotype in the Presence of a Dsg1 and
Dsg3 Autoantibody Pro®le
To the Editor:
Pemphigus foliaceus (PF) and pemphigus vulgaris (PV) are two
autoimmune blistering diseases presenting with distinct but related
antigenic speci®city and histopathologic features (Amagai, 1995;
Stanley, 1995; Suter et al, 1998; Anhalt and Diaz, 2001). In both
diseases, the target antigens are transmembrane components of
desmosomal junctions that mediate strong intercellular adhesion
between keratinocytes (Green and Gaudry, 2000). In PF, the
autoantibodies target desmoglein (Dsg) 1, and in PV Dsg3 (Amagai,
1995; Stanley, 1995; Suter et al, 1998; Anhalt et al, 2001). Whereas
the autoantibodies bind to all sites within strati®ed squamous
epithelia where the antigen is expressed, blister formation is
restricted to speci®c locations. In PF, split formation occurs in the
subcorneal zone of the epidermis where Dsg1 is present without
Dsg3, and in PV blisters form between basal and suprabasal layers of
initially mucous membranes where Dsg3 is present without Dsg1
Table I. ATP2C1 mutations in patients with HHD
Patient Age/sex
Age of
onset Mutationa
Location of
mutation
Nucleotide
changeb Consequence
1 55/M 51 R153X exon 7 457C®T nonsense
2 54/M 38 C490F exon 17 1469G®T missense
3 70/M 40 L584P exon 19 1751T®C missense
4 58/M 40 2460delG exon 25 CATGTT®CATTT franeshift (PTC+5 aa)
5 62/F 55 1259+1g®a intron 12 TGGgta®TGGata skip exon 12 (PTC)
6 45/M 30 ND
7 45/M 20 ND
8 33/M 27 ND
9 44/M 30 ND
10 63/M 62 ND
aNumbering of the amino acids refers to the peptide sequence.
bNumbering of the nucleotides refers to ATP2C1 cDNA sequence, with the ®rst nucleotide of ATG initiation codon as 1. Bases in the exons are denoted by uppercase
letters and bases in the introns by lowercase letters. PTC+n aa indicates that the premature termination codon is ''n'' amino acids downstream of the mutation. X, stop co-
don; ND, ``not detected''; PTC, premature termination codon.
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(Shirakata et al, 1998; Mahoney et al, 1999). These observations led
to the prevailing model that in pemphigus the unaffected Dsg
isoform can compensate for the autoantibody-targeted Dsg, and
that consequently blisters only form in zones with exclusive
expression of the targeted Dsg (Shirakata et al, 1998; Mahoney et al,
1999; Wu et al, 2000). Based on the histopathologic and serologic
features, the two pemphigus forms are thus clearly distinct.
Nevertheless, rare cases have been reported where histopathologic
changes of PV have shifted to PF lesions and vice versa (Iwatsuki et
al, 1991; Kawana et al, 1994; Chorzelski et al, 1995; Chang et al,
1997; Ishii et al, 2000; Komai et al, 2001; Sami et al, 2001). These
shifts are usually associated with a change in the pro®le of Dsg1 and
Dsg3 antibodies. Even rarer cases have been published where PF
and PV coexist histopathologically without shifting towards one or
the other form (Chorzelski et al, 1995; Komai et al, 2001). In all
these latter cases with coexisting PF and PV, the concurrent lesions
on skin and mucous membranes correlated with antibodies against
Dsg1 and Dsg3 as well as acantholysis in both subcorneal and
suprabasilar localization.
We here report another unusual variant of these rare pemphigus
cases exhibiting coexisting PF and PV. In contrast to the previous
cases (Chorzelski et al, 1995; Komai et al, 2001), our patient never
developed oral lesions, despite skin lesions concomitantly in
suprabasilar and subcorneal localization and antibodies against
both Dsg1 and Dsg3.
Without a history of previous skin disease and in the absence of
any medication, a 51-y-old male developed itching scales and crusts
on the scalp in spring 1998. Six months later multifocal, pruritic
erythematous lesions appeared on the rest of the integument,
without loss of well being. The patient presented at our outpatient
clinic 1 y after onset of the skin lesions. Initially, clinical nosological
assignment was dif®cult. The lesions on the scalp were reminiscent
of extensive seborrhoeic dermatitis, whereas plaque-like lesions on
the nose resembled discoid lupus erythematosus or granulomatous
dermatosis (Fig 1a). The multifocal lesions on the trunk and
extremities, partly covered with hemorrhagic crusts, were remin-
iscent of eczema (Fig 1b), and a slightly elevated titer of IgE
pointed to possible atopic diathesis. Mucous membranes were not
affected.
The work-up based on the differential diagnosis listed above was
negative for antinuclear antibodies (ANA, dsDNA, and SS-A). A
biopsy taken from the back showed an unspeci®c, super®cial
perivascular and spongiotic dermatitis, and one taken from the nose
a pigmented solar keratosis. Direct immuno¯uorescence of the
biopsy from the nose demonstrated C3 (data not shown) and
granular IgG deposits (Fig 2a) along keratinocyte membranes.
The staining pattern for IgG gradually increased in intensity from
the stratum basale to the stratum granulosum. Subsequent indirect
immuno¯uorescence on both human skin and dog lip exhibited
intercellular antiepidermal antibodies at a titer of 1:512 with a
similarly graded pattern (Fig 2b). This pattern was particularly
visible on dog lip where no Dsg1 is expressed in the basal cell layer
(MuÈller et al, unpublished observation). In the meantime, the
patient developed a stable blister on his left ankle measuring 4 3 3
cm. A biopsy thereof showed a mid-epidermal cleft (data not
shown), whereas further biopsies from the scalp revealed epidermal
(Fig 3a) and infundibular acantholysis concomitantly located
subcorneally as well as suprabasally. This cleft formation typical of
PV and PF correlated with antibodies to both Dsg1 and Dsg3, as
demonstrated by western blot analysis and an enzyme-linked
immunosorbent assay (ELISA) using recombinant proteins
(Figs 3b, c; Amagai et al, 1999).
Dsg3 antibodies were present in the serum of the patient at a
lower titer than antibodies to Dsg1, consistent with the graded
staining pattern seen in the direct and indirect immuno¯uorescence
analyzes (Figs 2a, b). The presence of Dsg1 and Dsg3 antibodies of
the IgG4 isotype (revealed by western blot analysis), to which the
wide majority of the pathogenic pemphigus antibodies belong
(Rock et al, 1989; Bhol et al, 1995), was consistent with blister
formation in a subcorneal and suprabasal location of the skin.
Systemic corticosteroids (initially 1.5 mg prednisone per kg per d)
rapidly induced remission and correlated with little remaining
intraepidermal IgG deposits as seen after 1 y by direct iummuno-
Figure 2. Direct and indirect immuno¯uorescence. (a) A cryosection of a biopsy from the patient's nonin¯amed peri-lesional skin of the nose was
stained with FITC-labeled antihuman antibodies. Note that the granular aspect of IgG deposits likely results from clustering of the antigenic target
through cross-linking by the bivalent antibodies (de Bruin et al, submitted), which has been described in lesional and perilesional skin of pemphigus
patients (Burge et al, 1993; Hashimoto et al, 1995; Iwatsuki et al, 1999). (b) Cryosections of human skin and dog lip taken from healthy donors were
incubated with the patient serum in a dilution of 1:512 and revealed with antihuman antibodies. Note that the staining pattern is stronger in the
super®cial layers of the dog lip than in the deep epithelium where no Dsg1 is expressed (MuÈller et al, unpublished observation). Arrowheads point to the
basement membrane zone.
Figure 1. Macroscopic view of lesions. (a) Plaque-like lesions on the
nose resembled discoid lupus erythematodes or granulomatous
dermatosis. (b) Multifocal lesions on the upper trunk partly covered with
hemorrhagic crusts were reminiscent of eczema.
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¯uorescence (Fig 4a), and no detectable serum titer as determined
by indirect immuno¯uoescence analysis (Fig 4b) and ELISA
(Fig 4c). No recurrences have been observed within 2 y. In
conclusion, the ®ndings of epidermal blisters in a PF as well as PV
location in the presence of Dsg 1 and Dsg 3 antibodies, supported
by the fact that their clearance correlated with remission, provided
compelling evidence that either antibody was pathogenic, the Dsg1
antibodies but also the Dsg3 antibodies, despite the lack of mucosal
membrane involvement.
To directly address at the time point of our initial diagnosis
whether the mucosa of the patient remained unaffected because of
an unusual expression of Dsg1 in the deep layers of oral epithelium,
we performed a double labeling immuno¯uorescence study with
antibodies to Dsg1 and Dsg3 using the patient's oral mucosa and the
mucosa of a control donor (Fig 5a). The distribution of Dsg1 and
Dsg3, including desmoplakin, which was used as control for the
presence of intact desmosomes (Fig 5b), did not differ and was
found to correspond with that reported in the literature (Shirakata
et al, 1998). This indicated that the absence of lesion formation
in the patient's oral mucosa was not a consequence of an
abnormal Dsg1 expression by basal cells, but had to rely on a
different mechanism. Furthermore, even if some Dsg1 protein
was to be expressed that remained undetected by the
immuno¯uorescence analysis, lesions formation would neverthe-
less be expected, as pathogenic Dsg1 antibodies are present in
the serum of the patient.
Recently another patient has been described, presenting with
autoantibody deposits in the deep and upper epidermis, the sites
of Dsg3 and Dsg1 expression, respectively (Izumi et al, 1998).
Despite presumable presence of Dsg3 and Dsg1 antibodies (the
antigenic speci®city of the patient's serum was not identi®ed on
recombinant Dsg1 and Dsg3), no mucosal involvement was
observed. Similarly, eight patients have recently been reported
Figure 3. PV and PF phenotype. (a) Haematoxilin and eosinophil staining of a section of paraf®n-embedded tissue originating from the scalp of the
patient. The diamond indicates a blister in PF location and stars those in a PV location. (b) 2.5 ml and 5 ml, respectively, of supernatant from
baculovirus-infected insect cells producing the extracellular domain of Dsg1 (rDsg1) or Dsg3 (rDsg3) in fusion with the constant region of human IgG1
(Fc; Amagai et al, 1994), were loaded in triplicates and subjected to western blot analysis. One blot was incubated with normal human serum (left panel)
and the second with the patient serum (middle panel), both in a dilution of 1:100. The secondary antibody was in either case antihuman IgG4 coupled
to alkaline phosphatase (HP6025, Southern Biotechnology Associates). As a loading control the last blot (right panel) was incubated with antihuman IgG
coupled to AP, which binds to the Fc region of the fusion proteins. Antibody binding was revealed with Immun-Star Substrate Pack. (c) An ELISA
with the patient's serum was performed on recombinant Dsg1 and Dsg3 as described previously (Amagai et al, 1999). An index above 20 is considered
as speci®c.
Figure 4. Immunopathology and ELISA 1 y after remission.
(a)Cryosections from the scalp of the patient were tested by direct
immuno¯uorescence as described in Fig 2a, except that the
photographic exposure was prolonged to illustrate a faint anti-IgG
staining (as seen by the substantial back-ground in the dermis).
Arrowheads point to the basement membrane zone (also in (b)).
(b)Indirect immuno¯uorescence was performed as described in Fig 2b at
a dilution of the patients serum of 1:10. The nuclei were counter-stained
with DAPI. (c)The same serum as in (b) was tested by ELISA (Amagai et
al, 1999). The titer between 10 and 20 is considered as gray zone, and
below 10 as nonspeci®c.
VOL. 118, NO. 3 MARCH 2002 LETTERS TO THE EDITOR 553
presenting with a mixed antibody pro®le and no mucosal
involvement (Sami et al, 2001). Even though both of these
reports indicated that antibodies to Dsg1 and Dsg3 can be
present without lesions on mucous membranes, the patho-
genicity of the Dsg3 antibodies in these patients is questionable
because no suprabasal acantholysis has been demonstrated. The
situation was different in a dog with PV who developed blisters
in the deep layers of the epidermis but not in mucous
membranes (Olivry et al, 1992). Although it can presently not
be excluded that the pathogenesis in man and dog differ to
some extent, this latter case appears consistent with our ®nding
that the presence of pathogenic Dsg3 antibodies, which are able
to induce skin lesions in a PV localization, does not invariably
imply mucosal involvement.
What could account for lack of blister formation in the
mucosa despite the presence of pathogenic Dsg3 antibodies? It
could be argued that the titer of circulating Dsg3 antibodies in
our patient was too low to cause blisters in the mucosa but was
suf®cient for blister formation in the basal layers of the
epidermis. In these layers, the presence of pathogenic Dsg1
antibodies may exacerbate the effect of pathogenic Dsg3
antibodies, similarly as described by Mahoney et al (1999).
This enhancement would not occur in the mucosa as Dsg1
antibodies only bind to the basal layer of the skin and not to
that of mucous membranes. Nonetheless, a lower Dsg3 antibody
titer than the one measured in our study was found to cause
skin blisters and to also induce mucous membrane lesions in
another patient (Komai et al, 2001). Alternatively, we and
others have recently shown that lesion formation also depends
on the activation of intracellular signaling pathways (Kitajima et
al, 1999; Caldelari et al, 2001). Our studies demonstrated that
plakoglobin, a component of the desmosomal plaque, is essential
in this process and that its absence can abolish responsiveness.
Similarly as in plakoglobin null mutant cells (Caldelari et al,
2001), the pathogenic response mechanisms may be impaired in
the mucosa of some patients, protecting them from lesion
development. As our patient had a normal distribution pattern
of plakoglobin as compared with a healthy donor (Fig 5b), it
might be the lack of another, yet to be de®ned element of the
pathogenic signaling pathway that enables cells in the oral
Figure 5. Expression of desmosomal components in the mucosa of the patient. (a)Cryosections from the patient and a healthy donor were
incubated concomitantly with anti-Dsg1 (red; DG 3.10; recognizes also Dsg2) and anti-Dsg3 (green; RDI, Flanders, NJ) antibodies. After incubation
with the relevant secondary antibody, the tissue was ®xed with 2% paraformaldehyde and analyzed. (b)Cryosections were ®xed with 2%
paraformaldehyde and permeabilized with 0.5% Triton at room temperature for 15 min prior to incubation with plakoglobin-speci®c antibodies (PG
5.10; a kind gift of P. Wheelock, Nebryska Medical Center, Oyaha) or antibodies to desmoplakin (multiepitope cocktail, Progen, Germany). For each
antibody in (a) and (b) experimental settings and photographic exposures were held constant between the sections from the patient and the healthy
donor.
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mucosa of rare patients to resist pathogenic Dgs3 antibodies.
Such a mechanism would also explain the ®nding in the dog
patient (described above) with PV and no apparent PF lesions
(Olivry et al, 1992). Even though this explanation is still
speculative, in-depth analysis of such unusual cases will provide
us with further insight into the pathophysiology of pemphigus.
Furthermore, the elucidation of a mechanism leading to
``resistance'' to pathogenic antibodies would represent a potent
tool to develop the novel therapeutic strategies pemphigus
patients need.
In conclusion, we report a patient with features of both PF
and PV, including skin blisters in suprabasilar as well as a
subcorneal localization, but without mucosal involvement. This
represents, to the best of our knowledge, the ®rst example in
which concomitant PF and PV lesions are depicted within the
same location and more importantly, the ®rst example in
humans that provides evidence for the presence of circulating
pathogenic Dsg3 antibodies despite lack of mucosal involve-
ment. Even though such cases are probably very rare, they will
hopefully provide the key for a better understanding of the
pathophysiology of pemphigus.
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Increased Macrophage Migration Inhibitory Factor (MIF) in
the Sera of Patients with Extensive Alopecia Areata
To the Editor:
The pathogenesis of alopecia areata is still uncertain. The immune
system has been implicated in the pathogenesis of alopecia areata
and certain immunomodulatory cytokines play an important role in
this disease. The contribution of cytokines thought to be involved
in the pathogenesis of extensive alopecia areata has been studied.
Several lines of clinical and experimental data point towards
cytokines such as interleukin (IL)-1 and tumor necrosis factor
(TNF)-a, which may be crucial inducers of hair loss in alopecia
areata. For example, IL-1 has been shown to inhibit hair growth
in vitro and may be one of the factors triggering the arrest of hair
growth in vivo (Harmon and Nevins, 1993). TNF-a also inhibits
1Equal contribution.
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